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ANCA antigens, proteinase 3 and myeloperoxidase, are not (ANCA)-mediated effects because of the histologic pat-
expressed in endothelial cells. tern of necrotizing vascular injury that is the pathologic
Background. One hypothesis for the pathogenesis of vascu- hallmark of the ANCA-associated vasculitides. A mech-litis associated with antineutrophil cytoplasmic autoantibodies
anism whereby ANCA would physically interact with(ANCAs) proposes that ANCAs bind to ANCA antigens, such
as proteinase 3 (PR3) or myeloperoxidase (MPO), which are endothelial cells is not obvious. The specific ANCA anti-
produced by endothelial cells and expressed on their surfaces. gens [neutrophil granule proteins, proteinase 3 (PR3),
There are conflicting reports, however, on whether endothelial and myeloperoxidase (MPO)] should not be availablecells express the ANCA antigen PR3, and there are no reports
on the endothelial cell surface for interactions, based onon endothelial expression of MPO. The aim of this study was
to determine the presence or absence of PR3 and MPO mRNA published reports stating that the transcription of these
in both venous and arterial endothelial cells, employing standard genes is developmentally regulated and restricted to my-
reverse transcription-polymerase chain reaction (RT-PCR) eloid lineage cells [1, 2]. However, a major controversytechniques and also the quantitative and highly specific method,
has arisen over whether endothelial cells also can synthe-TaqMan PCR.
Methods. RT-PCR (with 3 primer sets) and TaqMan PCR, size ANCA antigens, especially PR3.
a method for detecting low copy transcripts, were used to probe The first report of PR3 expression in endothelial cells
for PR3 and MPO transcripts in human endothelial cells from was published in 1993 by Mayet et al [3]. In this study,umbilical vein (HUVEC) and artery (HUAEC) and from lung
C-ANCA (anti–PR3-autoantibodies) Fab92 fragmentsmicrovascular (HLMVEC). Cells were treated with interferon-g
(200 units/mL) or tumor necrosis factor-a (3 or 10 ng/mL) or were shown to bind an antigen expressed on IL-1a–
both. treated human endothelial cells (HEC). It was proposed
Results. Transcripts for PR3 and/or MPO were not detected that cytokine treatment induced the membrane expres-in HUVEC, HUAEC, and HLMVEC by standard RT-PCR.
sion of PR3, based on their observations that peak stain-Analyses for PR3 protein confirmed that PR3 is not expressed
in HUVEC. HUVEC and HUAEC were negative for PR3 and ing was seen after two hours of incubation, while un-
MPO by TaqMan PCR. treated cells showed only scant staining. Mayet et al later
Conclusions. PR3 and MPO are not expressed in HUVEC, published data showing that C-ANCA were functionallyHUAEC, or HLMVEC. Endothelial cell presentation of en-
involved in changes in cell signaling events, resulting indogenous PR3 and MPO antigens is not involved in the patho-
genesis of ANCA-associated vasculitis. Alternative explana- the induction of E-selectin and vascular cell adhesion
tions need to be explored to determine the pathogenic effect molecule (VCAM) expression [4, 5]. In the case of
of ANCAs.
VCAM expression, however, C-ANCA binding to endo-
thelial cells did not require cytokine induction of PR3
expression. The data spurred a novel theory of howThe endothelium has often been considered a pos-
ANCA might mediate injury to the vessel walls, that is,sible target of antineutrophil cytoplasmic autoantibody
direct antibody–antigen interactions on the endothelial
cell surface. Recently, several more reports have de-1See Editorial by Cohen Tervaert, p. 2171.
scribed C-ANCA–related effects on endothelial cell func-
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(HUVECs) [10]. Resolution of the issue of endothelial and MPO, was used as a positive control. HL60 cells
were cultured in RPMI, with Pen/Strep (100 units penicil-expression of ANCA antigens is required to move for-
ward toward the elucidation of the pathogenesis of lin, 100 mg streptomycin; GIBCO), and 10% heat-inacti-
vated FBS.ANCA disease.
The aim of this study was to systematically address
Cytokine treatmentthe question of PR3 expression by employing standard
reverse transcription-polymerase chain reaction (RT- Human umbilical vein endothelial cells, HMVEC-L,
and EA.hy926 cells were treated with 3 ng/mL (30 min)PCR) techniques and also the quantitative and highly
specific method TaqMan PCR to detect PR3 and MPO or 10 ng/mL (120 min) recombinant human tumor necro-
sis factor-a (TNF-a; Sigma Chemical Co., St. Louis, MO,mRNA in endothelial cells. We examined three cell
types, including vein endothelial, arterial endothelial, USA). HUAECs and HUVECs were treated with re-
combinant human interferon-g (IFN-g; Genzyme, Cam-and lung microvascular endothelial cells. The data pre-
sented here indicate that PR3 and MPO are not synthe- bridge, MA, USA) at 200 U/mL (6 h), TNF-a at 10
ng/mL (6 h), or IFN-g plus TNF-a.sized in endothelial cells.
RNA isolation and reverse transcription
METHODS
Cells were harvested at 80% confluency. Media were
Cell culture removed, and RNA STAT-60 (Tel-Test “B,” Friends-
wood, TX, USA) was added to the monolayer withoutHuman umbilical vein endothelial cells and human
umbilical arterial endothelial cells (HUAEC) from rinsing. Detached cells were collected and included in
the RNA preparation. Total RNA was extracted usingpooled donors were isolated in house from human umbil-
ical cord using collagenase (125 U/mL) in Hank’s buf- the supplied protocol. Reverse transcriptase (RT) reac-
tions contained 1 mg total RNA in a 20 mL reaction,fered saline solution (HBSS). Cells were grown on gela-
tin-coated tissue culture plates in M199 medium, 15% containing 200 units of Moloney murine leukemia virus
reverse transcriptase, 50 mmol/L Tris-HCl (pH 8.3), 75fetal calf serum (FCS; GIBCO, Grand Island, NY, USA),
glucose (4.5 g/L), 0.1 mol/L HEPES, l-glutamine (200 mmol/L KCl, 3 mmol/L MgCl2, 10 mmol/L dithiothreitol
(DTT), 40 units RNAse inhibitor and 0.5 mg oligo(dT)15mmol/L; GIBCO), Pen/Strep (100 units penicillin, 100
mg streptomycin; GIBCO), heparin (750 U/mL), and (Promega, Madison, WI, USA). Controls were imple-
mented to detect DNA contamination in the RNA prep-endothelial cell growth supplement (ECGS; 50 mg/mL;
Becton Dickinson, Mountain View, CA, USA) in 5% arations (2RT) by replacing the RT with 1 mL of H2O.
Total RNA, diethyl pyrocarbonate-treated H2O, andCO2. Endothelial cells were characterized by morphol-
ogy and by positive staining for von Willebrand factor oligo(dT)15 were incubated for two minutes at 708C
and quickly cooled in ice. dNTPs and RT were thenby immunofluorescence (IF). HUVEC (passage 3) and
HUAEC (passage 3) from pooled donors, purchased added and incubated for 60 minutes at 428C. The reaction
was inactivated at 978C for five minutes. The volumefrom Clonetics Corporation (San Diego, CA, USA),
were cultured on standard tissue culture plates in the was increased to 100 mL using diethyl pyrocarbonate
(DEPC)-treated H2O.endothelial cell basal medium (EBM). Supplements pro-
vided were 6 mg bovine brain extract, 5 mg human endo-
Primer sequencesthelial growth factor, 0.5 mg hydrocortisone, 50 mg gen-
tamycin, and 2% fetal bovine serum (FBS). HMVEC- Primers were synthesized by the Oligonucleotide Syn-
thesis Facility (Department of Pathology, University ofLs (passage 6, human microvascular endothelial cells-
lung; Clonetics Corp., San Diego, CA, USA) from North Carolina at Chapel Hill): GAPDH forward primer,
59-TGA AGG TCG GAG TCA ACG GAT TTG GT-39,pooled donors were cultured on standard tissue culture
plates in medium provided (EGM-MV). Supplements GAPDH reverse primer, 59-CAT GTG GGC CAT
GAG GTC CAC CAC-39; PR3 primer set 1 (bp 178 toprovided were identical to HUAEC and HUVEC sup-
plements with the exception of 5% FBS. EA.hy926 cells 547), forward primer, 59-CTT GAT CCA CCC CAG
CTT CGT G-39, reverse primer, 59-GCA GAA GAA(a chimeric cell line containing A549 epithelial carci-
noma cell and HUVEC components), which express fac- GGT GAC CAC GGT GAC-39; PR3 primer set 2 from
Mayet et al [3] forward primer, 59-ATG GCC TCC CTGtor VIII-related antigen, were developed and donated
by Dr. C.J. Edgell (Department of Pathology, University CAG ATG CGG GGG-39, reverse primer, 59-CGG
AGG CAC TGA GGT TGG CTG GGC-39; PR3 primerof North Carolina at Chapel Hill, NC, USA). EA.hy926
cells were cultured in Dulbecco’s modified Eagle me- set 3, forward 59-CTTCTGCGGAGGCACCTTGATC-39,
reverse 59-GCGAGGGACGAAAGTGCAAATG-39;dium high glucose (DMEM-h) with Pen/Strep (100 units
penicillin, 100 mg streptomycin; GIBCO) and 10% FBS. MPO (bp 1654 to 1916) forward primer, 59-CAC CCT
CAT CCA ACC CTT CAT GTT C-39, MPO reverseA promyelocytic cell line, HL60, shown to express PR3
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primer, 59-CAT GTT CAG AGC AGG CAG GTC ng/mL for 24 hours and 50 ng/mL for 1 or 24 hours. Cells
were washed with PBS, fixed in acetone for 10 minutes,CAG-39.
and air dried. Slides were rehydrated for five minutes in
Polymerase chain reaction parameters PBS. Cells were incubated in primary antibody (diluted
in PBS plus 0.2% normal goat serum; Sigma Biosciences)Polymerase chain reaction was done using the Perkin
Elmer Thermal Cycler 9600 (Perkin Elmer Corp., Hay- for 30 minutes in a dark, humid container, washed twice
in PBS, and then incubated for 20 minutes with a second-ward, CA, USA). GAPDH primers were included in
each PCR reaction as an internal control. To detect con- ary fluorescein-labeled antibody. Primary antibodies in-
cluded mouse anti-PR3 (5 mg/mL, positive control), ataminating material in reagents, a sample was run minus
cDNA. The reactions consisted of cDNA (0.2 mg), 50 monoclonal antibody developed and donated by Jorgen
Wieslander (Wieslab) [11]. This antibody is character-mmol/L KCl, 10 mmol/L Tris-HCl (pH 8.3), 2 mmol/L
MgCl2, 200 mmol/L dNTP, 20 mmol/L of each primer ized by sensitive and specific binding to PR3 by indirect
IF using normal human neutrophils fixed in acetone. Theand two units of AmpliTaq DNA Polymerase (Perkin
Elmer). Samples were heated to 958C for two minutes conditions used for this positive control were those used
to detect the presence of PR3 in endothelial cells. Addi-to denature all cDNA prior to cycling. Parameters used
for primer set 1 for PR3 and for MPO primers were 35 tional primary antibodies included ANCA-positive hu-
man serum (1:100) and purified IgG (5 mg/mL), normalcycles of 948C for 45 seconds, 578C for 60 seconds, and
728C for 120 seconds. The Hot Start technique was imple- human serum (1:100), and purified IgG (5 mg/mL; Pierce,
Rockford, IL, USA), rabbit antihuman von Willebrandmented for MPO primers by heating all samples to 858C
for five minutes prior to its addition to reduce nonspecific factor (5 mg/mL; Dako Corporation, Carpinteria, CA,
USA), and mouse antihuman VCAM-1 (5 mg/mL; Gen-priming. Parameters used for PR3 primer set 2 were 30
cycles of 958C for 60 seconds, 628C for 60 seconds, and zyme Diagnostics). A negative control, containing dilu-
ent in place of a primary antibody, was included with728C for 60 seconds. Parameters used for PR3 primer
set 3 were 40 cycles of 948C for 45 seconds, 608C for 60 each secondary antibody (Jackson Immunoresearch
Laboratories, St. Louis, MO, USA) to detect backgroundseconds, and 728C for 120 seconds.
fluorescence. The mouse anti-PR3 antibody was used
Protein extraction and immunoblotting as a positive control antibody against PR3. The rabbit
antihuman von Willebrand factor was used as a positiveCells were rinsed twice in calcium-free and magne-
sium-free phosphate-buffered saline (PBS). A volume of control for the endothelial cells, and the mouse anti–
VCAM-1 was used to test TNF-a activation at variousnonreducing Laemmli sample buffer (1008C) was added
directly to the dish to achieve a final concentration of time points.
3 3 106 cells/mL. Cell lysates were collected and boiled
PCR sensitivity assayfor five minutes. Aliquots equal to approximately 2 3
105 cells were subjected to sodium dodecyl sulfate-poly- PR3cDNA/pAcC4 plasmid was a generous gift from
Dr. Joelle E. Gabay (Cornell University Medical Col-acrylamide gel (SDS-PAGE; 15%) electrophoresis and
transferred to nitrocellulose (Schleicher and Schuell, lege, Division of Infectious Diseases). Full-length PR3
cDNA was digested from the pAcC4 vector and purifiedKeene, NH, USA) at 100 V for one hour. Blots were
blocked in 10% milk-TBST (Tris-buffered saline con- using the Qiagen Gel Extraction Kit (Qiagen, Chats-
worth, CA, USA). Serial dilutions based on the actualtaining 0.05% Tween 20) for one hour at room tempera-
ture. Antibodies used were mouse antihuman PR3 [11], copy number of the cDNA were subjected to RT-PCR
using PR3 primer set 3 as described previously in thiskindly donated by Jorgen Wieslander (Wieslab, AB,
Lund, Sweden), goat antihuman pp90rsk antibody (Santa article. Amplified products were analyzed by agarose gel
electrophoresis and were visualized by ethidium bromideCruz Biotechnology, Santa Cruz, CA, USA), and anti-
mouse or antigoat secondary conjugated to horseradish staining.
peroxidase (Chemicon, Temecula, CA, USA).
TaqMan PCR
PR3 protein analysis by immunofluorescence Quantitative RT and PCR assays were performed in
duplicate on a Perkin-Elmer 7700 TaqMant PCR ma-The Department of Pathology (University of North
Carolina at Chapel Hill), using standard clinical meth- chine using a Taqman EZ-RT PCR kit (Perkin-Elmer).
Standard RT extension, PCR annealing, and amplifica-ods, performed the IF analyses. HUVECs (passage 3)
were subcultured onto glass chamber slides (Nalge Nunc tion temperatures were used as detailed by the Perkin-
Elmer TaqMan manual. Primers and TaqMan probesInternational, Rochester, NY, USA) and coated with
endothelial cell attachment factor (Sigma Biosciences, were designed using the Perkin-Elmer computer pro-
gram Primer Express. The forward primer for humanSt. Louis, MO, USA). Cells were treated with TNF-a
(Genzyme Diagnostics, Cambridge, MA, USA) 25 PR3 was TGT CAC CGT GGT CAC CTT CTT (bp 465
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Fig. 1. Agarose gel analyses of RT-PCR assays performed on endothelial cells to detect proteinase 3 (PR3) message using conditions and primers
developed in our laboratory. HL60 cells positive for PR3 message (a–e, lane 9). Untreated human epithelial cells and umbilical vein (HUVEC)
and artery HUAEC (a–e, lane 1); tumor necrosis factor-a (TNF-a)–treated cells (a, b, and c, lane 3, 3 ng/30 min; lane 5, 3 ng/2 h; lane 7, 10 ng/
2 h); interferon-g (IFN-g) 200 U/mL (d and e, lane 5); TNF-a 10 ng/6 h (d and e, lane 3); TNF-a plus IFN-g (d and e, lane 7). Minus reverse
transcriptase controls (2RT; a–e, lanes 2, 4, 6, 8, and 10). GAPDH amplification of approximately 1000 bp can be observed in lanes 1, 3, 5, 7,
and 9 (a–e). Abbreviations are: M, molecular weight marker; C, -DNA control; bp, base pairs.
to 485), and the reverse primer was CCC CAG ATC ated by RT-PCR. Neither untreated endothelial cells
showed amplification of PR3. The predicted band of 370ACG AAG GAG TCT AT (bp 589 to 611). The probe
was FAM-TTG CAC TTT CGT CCC TCG CCG- bp was amplified in HL60 cells (Fig. 1). PCR reactions
were performed using the primer set and parametersTAMRA (bp 504 to 524). For MPO, primers were CCA
GGA AGC CCG GAA GAT (bp 1492 to 1509), CGG described by Mayet et al [3]. PR3 amplification (expected
size of 276 bp) was not detected in EA.hy926, HUVECs,AAG GCA TTG GTG AAG A (bp 1641 to 1659) and
FAM-TGC CCA CGT ACC GTT CCT ACA ATG HMVEC-Ls, or HUAECs in both treated and non-
treated cells (Fig. 2).ACT C-TAMRA (bp 1590 to 1617) for forward, reverse,
and probe oligos, respectively. To increase sensitivity
Analysis of MPO transcriptsfor low-copy number mRNAs, primer concentration was
increased to 600 mmol/L and probe increased to 200 Polymerase chain reaction was performed to deter-
mmol/L. Fifty nanograms of total RNA were used per mine whether MPO is expressed in HUAECs and/or
reaction. For the dilution curve calibration, HL60-posi- HUVECs. The predicted 262 bp product was observed
tive RNA was serially diluted into samples containing in the HL60-positive control cell line (Fig. 3). MPO tran-
50 ng of HUVEC RNA to maintain the overall quantity scripts were not detected in the nontreated cells or in
of RNA in each sample. Relative quantitation was deter- the treated cells (Fig. 3). EA.hy926 cells and HMVEC-L
mined by standard 2(2DDCt) calculations. were also negative for MPO (data not shown). The data
indicate that MPO is not expressed in endothelial cells.
RESULTS Analysis of PR3 protein
Analysis of PR3 transcripts Proteinase 3 protein was not detected in HUVEC by
IF (Table 1), using two anti-PR3 antibodies. PR3 reactiv-To test for PR3 transcripts in endothelial cells, RT-
PCR was used with primers established in our laboratory. ity was negative in 17 out of 18 reactions, although as
shown, in this particular experiment, a slight positivecDNA was amplified in the positive-control HL60 cells
(Fig. 1), resulting in a band of expected size of 370 bp. was recorded in one sample. Repeat experiments showed
this to be a false positive because of the high background.PR3 was not detected in the untreated HUVECs and
HUAECs or in the TNF-a–treated cells (Fig. 1). IFN-g PR3 protein was not detected by Western analysis (Fig.
4) of untreated HUVECs (lane 2) or after TNF-a treat-or a combination TNF-a 1 IFN-g was added to HU-
VECs and HUAECs, and PR3 gene activation was evalu- ment (lanes 3 through 6). Purified PR3 protein (lane 1)
Pendergraft et al: Endothelial cells do not express PR3 or MPO 1985
Fig. 2. Agarose gel analyzes of RT-PCR assays performed on endothelial cells to detect PR3 message using conditions and primers developed
by Mayet et al. Untreated EA.hy926 cells (a, lane l), HUVEC (b and e, lane 1), human lung microvascular endothelial cells (HLMVEC; c, lane
1); treated with TNF-a 3 ng/mL for 30 minutes (a, b, and c, lane 3); TNF-a 3 ng/mL for two hours (a, b, and c, lane 5); TNF-a 10 ng/mL for two
hours (a, b, and c, lane 7). HUAECs (d) and HUVECs (e) treated with TNF-a 10 ng/mL for six hours (d and e, lane 3), IFN-g 200 U/mL for six
hours (d and e, lane 5), and TNF-a 10 ng/mL plus IFN-g 200 U/mL for six hours (d and e, lane 7). The HL60 cells were used as a positive control
for PR3 message (a–e, lane 9). 2RT controls were implemented for each sample (a–e, lanes 2, 4, 6, 8, and 10). M, molecular weight marker; C,
-DNA control; bp, base pairs.
Fig. 3. Agarose gel analyses of RT-PCR
assays performed on endothelial cells to detect
myeloperoxidase (MPO). HL60-positive con-
trol for MPO expression (a and b, lane 9).
MPO transcripts were not detected in the non-
treated cells (a and b, lane 1) or in the treated
cells (a and b, lane 3, TNF-a 10 ng/6 h; lane
5, IFN-g 200U/mL; lane 7, IFN-g 1 TNF-a
6 h). 2RT controls were implemented for each
sample (lanes 2, 4, 6, 8, and 10, a and b). Ab-
breviations are: M, molecular weight marker;
C, -DNA control; bp, base pairs.
ran at a slightly lower mobility than PR3 in HL60 cells. PR3 cDNA were prepared, and PCR was performed
using a third set of PR3 primers (Fig. 5). Based on theseThe nitrocellulose was reprobed with anti-pp90rsk to con-
firm that similar amounts of protein were loaded. data, if there were 100 or more copies (lane 4) of PR3
present in the total reaction, they should have been de-
PCR sensitivity analysis tected.
If PR3 and/or MPO mRNA were present in HUVECs,
Determination of potential PCR inhibitory factors init is highly unlikely that we would not have detected it,
HUVEC and HUAEC preparationsconsidering that PCR technology is sensitive enough to
detect 10 molecules or less of mRNA per cell [12]. Since One explanation for the lack of PR3 amplification in
HUVECs and HUAECs could be that the PCR is inhib-200 ng of total RNA (roughly 20,000 cells) were used
for each RT reaction in this study, there would have ited by some component of the HUVEC or HUAEC RNA
samples. To test this hypothesis, HL60 cDNA (at varyingbeen sufficient material to amplify any existing low levels
of PR3 and/or MPO message. Cytokine-induced tran- concentrations) was spiked into HUVEC or HUAEC
cDNA. Standard RT-PCR, using primer set 3, was per-scripts should have been present, since the half-life of
MPO and PR3 transcripts is approximately 3.5 hours formed. There was a hint that there might be inhibition
of PR3 amplification in HUVECs; therefore, we repeated[13]. However, to test the level of detection of PCR in
our system, serial dilutions of the purified full-length the experiment using the more quantitative TaqMan PCR,
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Table 1. Analysis of PR3 protein expression
by immunofluorescence
Passage [TNF] Hours Primary antibodies Results
3 — — Mab anti-PR3 negative
3 — — hu anti-PR3 negative
4 — — Mab anti-PR3 negative
4 — — hu anti-PR3 negative
5 — — hu anti-PR3 negative
3 20 ng/mL 1 hour Mab anti-PR3 11cyto
3 20 ng/mL 1 hour hu anti-PR3 negative
3 20 ng/mL 2 hours Mab anti-PR3 negative
3 20 ng/mL 2 hours hu anti-PR3 negative
3 20 ng/mL 3 hours Mab anti-PR3 negative
3 20 ng/mL 3 hours hu anti-PR3 negative
4 25 ng/mL 24 hours Mab anti-PR3 negative
4 25 ng/mL 24 hours hu anti-PR3 negative
4 50 ng/mL 1 hour Mab anti-PR3 negative
4 50 ng/mL 1 hour hu anti-PR3 negative
4 50 ng/mL 24 hours Mab anti-PR3 negative
4 50 ng/mL 24 hours hu anti-PR3 negative
5 50 ng/mL 1 hour hu anti-PR3 negative
Fig. 5. PR3 plasmid PCR sensitivity assay. Purified PR3 cDNA wasAbbreviations are: PR3, proteinase 3; [TNF], tumor necrosis factor concentra-
tion; Mab, monoclonal antibody; hu, human. quantitated and diluted based on copy number. Diluted samples were
then subjected to PCR. Lanes 1, 2, 3, 4, and 5 represent PCR amplifica-
tion of 10,000, 1,000, 500, 100, and 5 copies starting material, respec-
tively. Abbreviation M is molecular weight marker.
ates fluorescence when it is cleaved. The fluorogenic
probe is an oligonucleotide designed to bind between
the two PCR primers to the target cDNA, and is labeled
with a reporter and a quencher dye. In the intact probe,
the quencher dye suppresses the fluorescence of the re-
porter dye. During the polymerase extension steps, the
Thermus flavus exonuclease activity cleaves the hybrid-
ized probe, resulting in the separation of the quenching
dye from the fluorescent dye. When stimulated, the fluo-
rescence intensity is proportional to the amount of PCR
product synthesized. Fluorescence is monitored every
cycle for both the gene of interest and GAPDH. The
threshold cycle (CT value) is the cycle number in which
the PCR amplification as shown by increasing fluores-
cence is linear at a threshold above background. After
Fig. 4. Western blot probed with MaPR3 antibody (Wieslab, AB, completion of amplification, the CT values of the samples
Lund, Sweden). Purified PR3 (lane 1; kindly donated by Jorgen Wies-
are normalized based on the CT values for the GAPDH,lander); HUVEC untreated (lane 2); TNF-a 30 minutes (lane 3), 1 hour
(lane 4), 3 hours (lane 5), and 4 hours (lane 6). The nitrocellulose was which show the relative amounts of input RNA used for
reprobed with anti-pp90rsk to confirm protein loading. each sample. Theoretically, TaqMan has the ability to
detect a single transcript per sample. A typical TaqMan
data printout is in Figure 7, which shows a standard
dilution curve of HL60 RNA, spiked into HUVEC RNAand we saw no inhibitory activity in either HUAECs or
(to attain 50 ng total RNA starting material) probed forHUVECs. We conclude that HL60 PR3 was amplified
PR3 transcripts. Fluorescence on the y axis is plottedin a HUAEC background (Fig. 6, lanes 3 and 4) and in
against PCR cycle number on the x axis. The log increasea HUVEC background (Fig. 6, lanes 7 and 8).
in fluorescence intensity is proportional to transcript
Specific and quantitative TaqMan PCR assessment of copy number. PR3 mRNA in 50 ng of HL60 RNA pro-
PR3 and MPO mRNA duced a CT value of 17. A tenfold dilution of HL60
RNA starting material pushed the detection level up toTaqMan is a one-tube RT-PCR technique [14]. The
21 cycles, 100-fold up to 25 cycles, 1000-fold to 28 cycles,assay is based on the 59 nuclease activity of the Thermus
flavus polymerase and a fluorogenic probe, which gener- 3300-fold to 30 cycles, 10,000-fold to 32 cycles, and
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Fig. 6. PR3 RT-PCR assay for factors that
inhibit amplification in endothelial cell prepa-
rations. TNF-a 10 ng/mL treated HUAECs
(lane 3, 1:100 HL60 cDNA; lane 4, 1:10,000
HL60 cDNA) and HUVECs (lane 7, 1:100
HL60 cDNA; lane 8 1:10,000 HL60 cDNA).
TNF-a 10 ng/mL treated HUAECs (lane 6)
and HUVECs (lane 10) without HL60 cDNA.
HL60-positive control (lane 2). Abbreviation
M is molecular weight marker.
33,000-fold to 35 cycles (100,000-fold dilution showed no could have some transcription of the PR3 gene. How-
amplification after 40 cycles; data not shown). Because ever, we emphasize that our studies included the use of
the HL60 RNA was added to HUVEC RNA and ampli- umbilical vein endothelial cells harvested on site from
fication of PR3 was observed, it can be concluded that multiple donors, as well as commercial preparations of
in TaqMan PCR PR3 amplification was not inhibited, umbilical vein endothelial cells and endothelial cells
as was shown for standard PCR, by some unknown agent from sites not previously examined, including arterial
in the HUVEC preparations. Although TaqMan does and lung microvascular cells. Our analyses included eval-
not require post-PCR sample agarose gel analysis, the uations of cells exposed to two different cytokines har-
samples generated were evaluated by ethidium bromide vested at multiple times after treatment. Therefore, the
staining. Figure 7 (lanes 1 through 6) shows the HL60 findings in the present study make it highly unlikely that
dilution curve. PR3 production by an endothelial cell is a common and
To determine whether HUVECs or HUAECs express abundant feature, and that such a production would be
PR3, the TaqMan reactions were performed. Of the 36 responsible for the major pathogenic events in ANCA-
HUVEC and HUAEC samples tested (from 4 individual associated systemic vasculitis.
experiments), there was no amplification detected of The demonstration that the PR3 message could be
PR3 after 40 cycles. CT values for HUVECs and HU- amplified in HUVEC RNA spiked with small amounts
AECs were 40 and were off the scale of the graph (Fig. 7). of PR3-positive HL60 RNA rules out the possibility that
This means that if PR3 message is present in HUVECs or the RT-PCR reactions were blocked in some way in the
HUAECs, then the level of PR3 mRNA is 120,000-fold HUVEC preparations.
less than that in HL60 cells. Similar experiments and To our knowledge, this is the first report of the applica-
results were obtained for MPO expression in HUVECs tion of TaqMan PCR to address the issue of endothelial
and HUAECs relative to HL60 expression (Fig. 8). cells expressing PR3. The high sensitivity, simplicity, and
reproducibility of the real-time RNA quantitation, com-
bined with its wide dynamic range, make this methodDISCUSSION
especially suitable. TaqMan PCR is a widely acclaimedOne hypothetical mechanism of ANCA-associated
method that is now being applied to clinical issues, suchvasculitis is through direct interactions between the vas-
as assessment of hepatitis C virus load in serum samplescular endothelial cells and the autoantibodies. This inter-
[15], detection of gene amplification in cancers [16–18],action is proposed to be facilitated through endothelial
detection of mycobacterium tuberculosis DNA in spu-expression and presentation of the PR3 antigen, the same
tum [19], and detection of Salmonella in raw meat [20].antigen expressed by neutrophils. The studies described
We believe that the use of TaqMan PCR in our investiga-here use conventional RT-PCR and TaqMan PCR to
tions has provided the accuracy and reliability necessaryaddress the hotly debated question of whether endothe-
to be confident in our results.lial cells express PR3. Our data support the conclusion
P-ANCA (anti-MPO autoantibody) are associatedthat ANCA antigens PR3 and MPO are not expressed
with vasculitis as well; therefore, endothelial cell expres-by endothelial cells. These data do not completely rule
sion of MPO would be equally important in the patho-out the possibility that endothelial cells from other or-
gans or from other individuals treated with other agents genesis of ANCA-mediated disease. The present study
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Fig. 7. TaqMan RT-PCR for PR3. HUVEC
(H) and HUAEC (I) samples were negative
for PR3 showing Ct values of 40, off the scale
of the graph. Serial dilutions of HL60 RNA
were added to HUVEC RNA (A–G) to estab-
lish a standard curve.
Fig. 8. TaqMan RT-PCR for MPO. HUVEC
(H) and HUAEC (I) samples were negative
for PR3 showing Ct values of 40, off the scale
of the graph. Serial dilutions of HL60 RNA
were added to HUVEC RNA (A–G) to estab-
lish a standard curve.
represents the first published data testing for MPO neutrophil primary granule enzymes is generally coregu-
lated [21–23]. Also, the fact that PR3 and MPO functionsmRNA in endothelial cells. We predicted that if the PR3
gene was transcribed in endothelial cells, and then the are interrelated would imply that coexpression would
be biologically favorable [24]. PR3 proteolytic activityMPO gene would be also, since de novo synthesis of
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requires MPO-derived products to oxidize and inactivate Antineutrophil cytoplasmic autoantibody interactions
the PR3 inhibitor a1-antitrypsin. MPO message could with antigens planted on bystander cells, such as endo-
not be detected, lending support to the conclusion the thelial cells, may be a contributing factor to vascular
PR3 is not expressed in endothelial cells. damage [46]. Alternatively, a recent study by De Bandt
This finding is not surprising in light of the published et al described antigens on endothelial cells that were
data concerning the requirements for transcription of recognized by C-ANCA, none of which were PR3 [10].
the PR3 gene. Two transcriptional control elements are C-ANCA were shown to complex with surface proteins
essential for the expression of PR3: PU.1 and CG [1]. The of 82, 110, and 125 kD in size. If these data are substanti-
PU.1 (Spi-1) transcription factor is itself predominantly ated, they may provide one explanation for reported
expressed in myeloid and B cells [2, 25]. It is a member observations of ANCA-mediated endothelial effects.
of the ETS oncogene family of transcriptional activators In summary, our study indicates that endothelial cells
critical for development of both these lineages [26], as do not express ANCA antigens, PR3 and MPO, and
demonstrated in PU.12/2 mice that lack both lymphoid confirms the report by King et al [9].
and myeloid cells [27]. Thus, PU.1 expression is proposed
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